Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,008,201
  • Shares Outstanding, K 40,490
  • Annual Sales, $ 726,410 K
  • Annual Income, $ 7,030 K
  • EBIT $ 76 M
  • EBITDA $ 166 M
  • 60-Month Beta 0.19
  • Price/Sales 1.38
  • Price/Cash Flow 6.41
  • Price/Book 1.53

Options Overview Details

View History
  • Implied Volatility 56.80% (+3.41%)
  • Historical Volatility 30.52%
  • IV Percentile 27%
  • IV Rank 19.77%
  • IV High 128.93% on 03/16/26
  • IV Low 39.03% on 08/20/25
  • Expected Move (DTE 24) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 1,063
  • Open Int (30-Day) 1,113
  • Expected Range 24.64 to 24.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.33
  • Number of Estimates 1
  • High Estimate $0.33
  • Low Estimate $0.33
  • Prior Year $0.39
  • Growth Rate Est. (year over year) -15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.96 +12.20%
on 04/07/26
25.32 -2.67%
on 04/20/26
+2.53 (+11.44%)
since 03/20/26
3-Month
19.67 +25.30%
on 01/28/26
25.32 -2.67%
on 04/20/26
+4.40 (+21.74%)
since 01/21/26
52-Week
18.80 +31.06%
on 01/20/26
27.64 -10.85%
on 09/03/25
-1.26 (-4.86%)
since 04/21/25

Most Recent Stories

More News
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026

BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 24.64 (-1.04%)
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures

-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated...

PCRX : 24.64 (-1.04%)
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 24.64 (-1.04%)
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting

-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE)...

PCRX : 24.64 (-1.04%)
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.

Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Years [i] ; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30% [ii] ...

PCRX : 24.64 (-1.04%)
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation

-- Issues Statement in Response to DOMA’s Nomination of Director Candidates --  -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pacira...

PCRX : 24.64 (-1.04%)
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.

Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Years i ; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30% ii ;...

PCRX : 24.64 (-1.04%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 24.64 (-1.04%)
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference

BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 24.64 (-1.04%)
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)

-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with iovera º for patients with osteoarthritis (OA) of the knee -- -- Data...

PCRX : 24.64 (-1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 26.16
2nd Resistance Point 25.61
1st Resistance Point 25.13
Last Price 24.64
1st Support Level 24.10
2nd Support Level 23.55
3rd Support Level 23.07

See More

52-Week High 27.64
Last Price 24.64
Fibonacci 61.8% 24.26
Fibonacci 50% 23.22
Fibonacci 38.2% 22.18
52-Week Low 18.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.